BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessNew Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma ModelBy Nasdaq OMXNov 14, 2016, 1:05 PM UTC
BusinessPreclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXOct 24, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent DevelopmentsBy Nasdaq OMXMar 9, 2016, 1:00 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
